Shares of Altimmune are down $1.70, or 16%, to $8.70 in morning trading after the company was the subject of a short report published earlier by Kerrisdale Capital.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALT:
- Altimmune call volume above normal and directionally bullish
- Altimmune reinstated with a Neutral at Goldman Sachs
- Unusually active option classes on open January 10th
- The biotech stocks to own in 2024, according to Piper Sandler
- Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
